Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. (1-6)-alpha-d-gluco-d-mannan
2. (1-6)-alpha-glucomannan
3. Glucomanna
4. Konjac Gluco-mannan
5. Konjac Glucomannan
6. Konjac Mannan
1. Glucomannoglycan
2. 76081-94-2
3. (glucomannan)n
4. (glucomannan)n+1
5. Chebi:17020
6. C01810
| Molecular Weight | 666.6 g/mol |
|---|---|
| Molecular Formula | C24H42O21 |
| XLogP3 | -9 |
| Hydrogen Bond Donor Count | 14 |
| Hydrogen Bond Acceptor Count | 21 |
| Rotatable Bond Count | 10 |
| Exact Mass | 666.22185834 g/mol |
| Monoisotopic Mass | 666.22185834 g/mol |
| Topological Polar Surface Area | 348 Ų |
| Heavy Atom Count | 45 |
| Formal Charge | 0 |
| Complexity | 918 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 19 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Cathartics
Agents that are used to stimulate evacuation of the bowels. (See all compounds classified as Cathartics.)
Drugs in Development
Details:
Glucomannan is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Obesity.
Lead Product(s): Glucomannan,Inulin,Psyllium
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Dietary Supplement
Sponsor: Center of New Medical Technologies | Triangel Scientific
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 03, 2024
Lead Product(s) : Glucomannan,Inulin,Psyllium
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Center of New Medical Technologies | Triangel Scientific
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Glucomannan is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
January 03, 2024
Details:
Konjac Glucomannan is a Dietary Supplement drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.
Lead Product(s): Glucomannan,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Dietary Supplement
Sponsor: Dicofarm | University of Toronto
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 15, 2018
Lead Product(s) : Glucomannan,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Dicofarm | University of Toronto
Deal Size : Inapplicable
Deal Type : Inapplicable
Konjac-Mannan Improves Glycemia and Other Risk Factors for CHD in T2DM
Details : Konjac Glucomannan is a Dietary Supplement drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
November 15, 2018
Details:
Konjac Glucomannan is a Dietary Supplement drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Insulin Resistance.
Lead Product(s): Glucomannan,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Dietary Supplement
Sponsor: Dicofarm | University of Toronto
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 15, 2018
Lead Product(s) : Glucomannan,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Dicofarm | University of Toronto
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Konjac-mannan in Individuals With Insulin-Resistance Syndrome
Details : Konjac Glucomannan is a Dietary Supplement drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Insulin Resistance.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
November 15, 2018
Details:
Glucomannan is a Dietary Supplement drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypoglycemia.
Lead Product(s): Glucomannan,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Dietary Supplement
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 13, 2015
Lead Product(s) : Glucomannan,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Glucomannan is a Dietary Supplement drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypoglycemia.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
January 13, 2015
Details:
Konjac Glucomannan is a Dietary Supplement drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Obesity.
Lead Product(s): Glucomannan,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Dietary Supplement
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 09, 2014
Lead Product(s) : Glucomannan,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Viscous Fibre Containing Foods on Satiety (Gel Form)
Details : Konjac Glucomannan is a Dietary Supplement drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
May 09, 2014
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info :
Registration Country : Germany
Glucomannan; Ascorbic Acid; Pantothenic Acid
Brand Name : Shapesticks®
Dosage Form : Stick Pack
Dosage Strength : 3G; 300MG; 24MCG
Packaging : 2G
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Germany
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
27
PharmaCompass offers a list of Glucomannan API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Glucomannan manufacturer or Glucomannan supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Glucomannan manufacturer or Glucomannan supplier.
A (1-6)-alpha-D-gluco-D-mannan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of (1-6)-alpha-D-gluco-D-mannan, including repackagers and relabelers. The FDA regulates (1-6)-alpha-D-gluco-D-mannan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. (1-6)-alpha-D-gluco-D-mannan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A (1-6)-alpha-D-gluco-D-mannan supplier is an individual or a company that provides (1-6)-alpha-D-gluco-D-mannan active pharmaceutical ingredient (API) or (1-6)-alpha-D-gluco-D-mannan finished formulations upon request. The (1-6)-alpha-D-gluco-D-mannan suppliers may include (1-6)-alpha-D-gluco-D-mannan API manufacturers, exporters, distributors and traders.
(1-6)-alpha-D-gluco-D-mannan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of (1-6)-alpha-D-gluco-D-mannan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right (1-6)-alpha-D-gluco-D-mannan GMP manufacturer or (1-6)-alpha-D-gluco-D-mannan GMP API supplier for your needs.
A (1-6)-alpha-D-gluco-D-mannan CoA (Certificate of Analysis) is a formal document that attests to (1-6)-alpha-D-gluco-D-mannan's compliance with (1-6)-alpha-D-gluco-D-mannan specifications and serves as a tool for batch-level quality control.
(1-6)-alpha-D-gluco-D-mannan CoA mostly includes findings from lab analyses of a specific batch. For each (1-6)-alpha-D-gluco-D-mannan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
(1-6)-alpha-D-gluco-D-mannan may be tested according to a variety of international standards, such as European Pharmacopoeia ((1-6)-alpha-D-gluco-D-mannan EP), (1-6)-alpha-D-gluco-D-mannan JP (Japanese Pharmacopeia) and the US Pharmacopoeia ((1-6)-alpha-D-gluco-D-mannan USP).
